Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.
Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...
Hosted on MSN
Stopping DNA damage in T cells during PARP inhibitor cancer treatment enhances antitumor effectiveness
The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...
Hosted on MSN
Advanced Prostate Cancer Update: Adding PARP Inhibitor To Standard Of Care Can Notably Improve Outcomes
Patients with a type of prostate cancer known as metastatic castration-sensitive prostate cancer (mCSPC), who have specific genetic mutations, were found to have improved survival by using a targeted ...
Preventing relapse of advanced ovarian cancer with PARP inhibitors is now an established strategy. As data from pivotal ...
Niraparib combined with abiraterone acetate and prednisone improved rPFS in mCSPC patients with HRR gene alterations, especially BRCA1/2 mutations. The combination showed potential in reducing ...
The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC). Now, Johnson & Johnson’s Akeega is giving the class a win in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback